Cuban medical internationalism

Al Mahmoud Medical Center, Qatar, adopts the geko™ device for prevention of venous thromboembolism (VTE) and reduction of edema (swelling)

Retrieved on: 
Thursday, December 8, 2022
Heart, Wound healing, Sky, Health, Thrombus, Venous thrombosis, Disease, Knee, Woman, Patient, Qatar National Vision 2030, Risk, Physician, Qatar National Company for Medical Projects, Internal medicine, Pulmonary embolism, Mouth ulcer, IPC, Stasis, Extremities, Blood, Swelling, Nursing, Obstetrics, Deep vein thrombosis, Pregnancy, DVT, Diabetes, Edema, Marketing, Thrombosis, Calf, Infarction, Leg, Diabetic foot, Maternal death, Common peroneal nerve, Cuban medical internationalism, VTE, FDA, Venous insufficiency, Consultant, Walking, General surgery, NICE, Dentistry, Pharmaceutical industry, Birth control, Medical device, Medical imaging, Hospital, Geko

Highly eminent, Dr. Mohammad Chikh Atieh, Consultant Internal Medicine at the Al Mahmoud Medical Center, adopts the geko device for the prevention of venous thromboembolism (VTE) and the reduction of edema (swelling) in all aspects of general surgery, obstetrics and gynaecology.

Key Points: 
  • Highly eminent, Dr. Mohammad Chikh Atieh, Consultant Internal Medicine at the Al Mahmoud Medical Center, adopts the geko device for the prevention of venous thromboembolism (VTE) and the reduction of edema (swelling) in all aspects of general surgery, obstetrics and gynaecology.
  • DOHA, Qatar, Dec. 8, 2022 /PRNewswire/ -- UK-based manufacturer, Firstkind Ltd (a Sky Medical Technology company) and Al Raya Medical Equipment, exclusive distributor for the geko device in Qatar, today announced adoption of the geko device by the Internal Medicine Clinic, at the Al Mahmoud Medical Center in Doha, Qatar.
  • The Al Mahmoud Medical Complex is a Qatari medical clinicthat delivers enhanced care to its patient through our integrated clinical practice.
  • Sky's products are tailored to different medical application areas, selling through strategic partnerships or distributors in each major clinical area.

Al Mahmoud Medical Center, Qatar, adopts the geko™ device for prevention of venous thromboembolism (VTE) and reduction of edema (swelling)

Retrieved on: 
Thursday, December 8, 2022
Heart, Wound healing, Sky, Health, Thrombus, Venous thrombosis, Disease, Knee, Woman, Patient, Qatar National Vision 2030, Risk, Physician, Qatar National Company for Medical Projects, Internal medicine, Pulmonary embolism, Mouth ulcer, IPC, Stasis, Extremities, Blood, Swelling, Nursing, Obstetrics, Deep vein thrombosis, Pregnancy, DVT, Diabetes, Edema, Marketing, Thrombosis, Calf, Infarction, Leg, Diabetic foot, Maternal death, Common peroneal nerve, Cuban medical internationalism, VTE, FDA, Venous insufficiency, Consultant, Walking, General surgery, NICE, Dentistry, Pharmaceutical industry, Birth control, Medical device, Medical imaging, Hospital, Geko

Highly eminent, Dr. Mohammad Chikh Atieh, Consultant Internal Medicine at the Al Mahmoud Medical Center, adopts the geko device for the prevention of venous thromboembolism (VTE) and the reduction of edema (swelling) in all aspects of general surgery, obstetrics and gynaecology.

Key Points: 
  • Highly eminent, Dr. Mohammad Chikh Atieh, Consultant Internal Medicine at the Al Mahmoud Medical Center, adopts the geko device for the prevention of venous thromboembolism (VTE) and the reduction of edema (swelling) in all aspects of general surgery, obstetrics and gynaecology.
  • DOHA, Qatar, Dec. 8, 2022 /PRNewswire/ -- UK-based manufacturer, Firstkind Ltd (a Sky Medical Technology company) and Al Raya Medical Equipment, exclusive distributor for the geko device in Qatar, today announced adoption of the geko device by the Internal Medicine Clinic, at the Al Mahmoud Medical Center in Doha, Qatar.
  • The Al Mahmoud Medical Complex is a Qatari medical clinicthat delivers enhanced care to its patient through our integrated clinical practice.
  • Sky's products are tailored to different medical application areas, selling through strategic partnerships or distributors in each major clinical area.

HealthTab™ Roll Out on Track and Operations Cashflow Positive

Retrieved on: 
Tuesday, October 11, 2022
News, Prediabetes, API, Diabetes, Glycated hemoglobin, Shoppers Drug Mart, Lipid profile, Disease, Growth, Pharmacy, Government of Canada, Workflow, Policy, Cuban medical internationalism, RWD, Patient, Degenerative disease, EGFR, Company, Strep, Health, Blood, Conditional sentence, Optimism, GLOBE, Pharmacist, Government, COVID-19, Biomarker, Renewable energy, Pharmaceutical industry, Health insurance, EU

We are on track to achieve the late-November target for full deployment.

Key Points: 
  • We are on track to achieve the late-November target for full deployment.
  • Once a pharmacy has HealthTab onsite there is a period of training and acclimating teams with the workflow.
  • In fact, HealthTab already has positive cash-flow from operations and is expected to significantly ramp up gross revenues over the next 12 months yielding target margins and profitability by Q2 2023.
  • These changes and commitments will have a significant impact on sales volumes in 2023, not to mention demand from pharmacy groups to install HealthTab.

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

Retrieved on: 
Tuesday, October 4, 2022
Algorithm, Concussion, Senior advisor, MT3, OPKO Health, Family, Prognosis, Diagnosis, BDNF, Posture, Psychology, Book, Sports medicine, Medtech, Brainbox, NIH, Patent, Athlete, GFAP, MRI, Developing Solutions, Inc, TBI, Neuroimaging, Health, László, J&J, Cuban medical internationalism, PTO, Solution, NFL, University, Unitus Seed Fund, UCLA School of Dentistry, Stryker, Biomarker, LECOM Health Challenge, Forme, Partner, Risk, Intellectual property, Board, Marketing, NSE, NRGN, Medical imaging, Pharmaceutical industry, Medical device, Biology, Medicine

RICHMOND, Va., Oct. 4, 2022 /PRNewswire/ -- BRAINBox Solutions, Inc announced today that the U.S. Patent & Trademark Office (PTO) issued a notice of allowance for a patent covering methods for detection of mild traumatic brain injury (mTBI), also known as concussion, using Brain Derived Neurotrophic Factor (BDNF). BDNF is an important component of the biomarker panel in the multi-modal diagnostic prognostic and prognostic solutions the company is developing for mTBI.

Key Points: 
  • "BRAINBox's test is the first to integrate blood biomarkers with functional testing for both the diagnosis and prognosis of mild TBI," said Donna Edmonds, BRAINBox Solutions' Chief Executive Officer.
  • "The new BDNF patent is an important addition to our broad, worldwide portfolio of patents covering biomarkers related to various aspects of diagnostic use.
  • The newly allowed patent is based on BRAINBox Solutions' discovery that a decrease in blood levels of BDNF alone are sensitive and specific in the detection of mild TBI.
  • BRAINBox Solutions is developing the first AI enabled, multi-modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion.

PALCUS to Celebrate Portuguese-American Success at 24th Annual Leadership Awards Gala

Retrieved on: 
Tuesday, August 23, 2022
Cuban medical internationalism, Master of ceremonies, Leadership, Ceremony, Ambassador, Honorary, Auction, Video game

WASHINGTON, Aug. 23, 2022 /PRNewswire/ -- The Portuguese American Leadership Council of the United States (PALCUS) announces that the full program of events is now available for the 24th Annual PALCUS Leadership Awards Gala. This year's festivities will take place in Washington, D.C.

Key Points: 
  • Weekend-long celebrations to include reception, brunch cruise, and Lusitanian Forum
    WASHINGTON, Aug. 23, 2022 /PRNewswire/ -- The Portuguese American Leadership Council of the United States (PALCUS) announces that the full program of events is now available for the 24th Annual PALCUS Leadership Awards Gala.
  • The 2022 PALCUS Leadership Awards Gala will be held on Saturday, October 8, at the Marriott Metro Center and will honor 7 awardees including artists and those recognized for lifetime achievement and community service.
  • We hope you can all join us in Washington D.C."
    The 2022 PALCUS Leadership Award recipients are:
    The 2022 Gala Committee is headed by PALCUS Directors Paula de Brito Cohen and Marta Silva.
  • There is a Silent Auction currently live and accepting bids at https://palcus-2.betterworld.org/auctions/explorers
    The PALCUS Leadership Awards Gala Weekend will include the following events:

HAIR LOSS AWARENESS MONTH 2022

Retrieved on: 
Thursday, July 21, 2022
Janus, Patient, COVID-19, Adult, Multimedia, Hair, Transplant, Conditioners, Skin, Digital, Woman, DHT, Baricitinib, CNC, Dietary supplement, Head, FUE, Technology, Platelet-rich plasma, Cuban medical internationalism, Alopecia areata, DNA, Hair loss, Physician, PRP, Industry, JAK, Scalp, Saliva, Immune system, Pressure regulator, FDA, Formula, TED, Man, Time, View, Telogen effluvium, Artificial intelligence, BOCA, Forbes, Regenerative medicine, Cosmetics, Medical imaging, Pharmaceutical industry, Boost, Sandalore

BOCA RATON, Fla., July 21, 2022 /PRNewswire/ -- With topics such as Alopecia Areata (the impetus of the infamous Oscars Slap) and Covid Related Hair Shedding continuing to make headlines, hair loss remains a top-of-mind issue for the masses. The American Hair Loss Association estimates that at least 80 million men and women are currently suffering from hair loss across the country. August officially marks Hair Loss Awareness Month (HLAM) and is advantageous for addressing advancements in treatments and technology. Internationally recognized, ABHRS-Certified Hair Restoration Surgeon Dr. Alan J. Bauman, and mastermind behind Biohacking Baldness, discusses the newest effective technology aimed at both preserving and restoring hair.

Key Points: 
  • The American Hair Loss Association estimates that at least 80 million men and women are currently suffering from hair loss across the country.
  • August officially marks Hair Loss Awareness Month (HLAM) and is advantageous for addressing advancements in treatments and technology.
  • TrichotestGenetic Hair Loss Testing uses state-of-the-art DNA microarray technology to identify the exact hair loss treatments that will perform best for the patient based on DNA analysis.
  • Based on a machine-learning algorithm, the HairMetrix system provides real-time analysis of hair density, hair caliber, and other metrics without the need for any hair trimming.

Universal Ibogaine Announces Chief Clinics Officer Dr Ian Rabb

Retrieved on: 
Thursday, November 4, 2021
Destiny, Aurora, Gimli, Diamond, Sola, Safety, Cocaine, Housing, THE, Interventionism, TSX, Jews, BC Children's Hospital Foundation, Medicalization, Program, Acquisition, UI, Community advisory board, Research, Opioid use disorder, Universal, Health Canada, Kelburn, AB, Oxycodone, Scotiabank, Education, Heroin, Science, LDS Family Services, Exercise, Leadership, News, Hotel manager, Clinical trial, Fentanyl, Time, Cuban medical internationalism, Child and family services, Plant, Business, Employment, THIS, Drug, Pharmaceutical industry, Medical device

CALGARY, AB, Nov. 4, 2021 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) ("Universal Ibogaine", "UI" or the "Company"), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to announce an expansion of its Executive Team and welcomes addiction treatment and clinic operations veteran Dr Ian Rabb as Chief Clinics Officer effective November 15, 2021.

Key Points: 
  • CALGARY, AB, Nov. 4, 2021 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) ("Universal Ibogaine", "UI" or the "Company"), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to announce an expansion of its Executive Team and welcomes addiction treatment and clinic operations veteran Dr Ian Rabb as Chief Clinics Officer effective November 15, 2021.
  • Dr Ian Rabb is one of the most recognized and respected leaders in Addiction Treatment in Canada today.
  • Dr. Ian Rabb is a certified Interventionist and addictions specialist who has helped thousands of people overcome addiction.
  • Dr Ian Rabb will take the helm at the Universal Ibogaines recently acquired addiction treatment facility located outside of Winnipeg, Manitoba.

Nemysis Ltd. Appoints Dr. David S. Sanders to Its Scientific Advisory Board

Retrieved on: 
Monday, September 27, 2021
Gluten-related disorders, Royal Hallamshire Hospital, Safety, British Society of Gastroenterology, SAB, E40, Patient, Non-celiac gluten sensitivity, MD, European, Epitope, Anemia, BSG, GLOBE, Endoscopy, University, Coeliac disease, Nutrient deficiency, Research, Cuban medical internationalism, Society, Dentistry, Flour, Dietary supplement

He is the current Chair of the Celiac UK Health Advisory Council.

Key Points: 
  • He is the current Chair of the Celiac UK Health Advisory Council.
  • "We are honoured to welcome Dr. Sanders on Nemysis' Scientific Advisory Board", said Danilo Casadei-Massari, Chairman and Chief Executive Officer of Nemysis Ltd. "As a world-renowned expert in Celiac Disease and Gluten Sensitivity, Dr. Sanders' appointment comes at a perfect time, as we continue to advance the development of our E40 technology, aimed at managing Celiac Disease and Gluten Sensitivity".
  • "We are excited to have David join Nemysis' SAB.
  • His clinical expertise in Celiac Disease and gluten intolerance will help us shaping the clinical development of E40", said Maria Cristina Comelli, Chief Scientific Officer of Nemysis.

The Prostate Cancer Foundation Appoints Charles J. Ryan, MD, As President And Chief Executive Officer

Retrieved on: 
Thursday, August 26, 2021
San Francisco, Department of Medicine – University of Pamplona, Clinical research, Mouse Models of Human Cancer database, Program, University, Prostate Cancer Foundation, Associate, Medicine, Hematology-Oncology and Stem Cell Transplantation Research Center, Family, Leadership, Masonic Cancer Center, Memorial Sloan Kettering Cancer Center, Research, Man, PCF, Death, Marquette University, Cuban medical internationalism, National Cancer Institute, Biology, Prostate cancer, Awareness, NCI, World, Food, Faculty, Alliance for Clinical Trials in Oncology, University of California, San Francisco, Hematology, Department, Ministry of Education (Malaysia), MD, Medical imaging

LOS ANGELES, Aug. 26, 2021 /PRNewswire/ --The Prostate Cancer Foundation (PCF), the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research, today announced that Charles (Chuck) J. Ryan, MD, an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer, has been appointed President and Chief Executive Officer.

Key Points: 
  • LOS ANGELES, Aug. 26, 2021 /PRNewswire/ --The Prostate Cancer Foundation (PCF), the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research, today announced that Charles (Chuck) J. Ryan, MD, an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer, has been appointed President and Chief Executive Officer.
  • "The Prostate Cancer Foundation's research model has set the standard for accelerating progress not just in prostate cancer but for many other disease-specific foundations.
  • The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research.
  • The Prostate Cancer Foundation research now impacts more than 70 forms of human cancer by focusing onimmunotherapy, the microbiome, and food as medicine.

August Is National Hair Loss Awareness Month

Retrieved on: 
Thursday, August 12, 2021
Multimedia, International Society, Genetic testing, American Board of Commissioners for Foreign Missions, Hair loss, AHLA, Man, Heredity, COVID, Certification, DHT, Science, Cuban medical internationalism, Hair, COVID-19, Artificial intelligence, Minoxidil, DNA, Dietary supplement, Textbook, FDA, FUE, Mass media, Forbes, View, Patient, Conference, Biofeedback Certification International Alliance, Technology, Formula, Social media, Metabolism, Plasma, Statistics, Scalp, Pandemic, Physician, Woman, Regenerative medicine, BOCA, Extracellular matrix, Saliva, Asprey, Faculty, Cosmetics, Medical device, Dentistry

BOCA RATON, Fla., Aug. 12, 2021 /PRNewswire/ -- According to the American Hair Loss Association (AHLA), an estimated 50 million men experience some level of hair loss and approximately 35 million women are also affected by thinning hair.

Key Points: 
  • BOCA RATON, Fla., Aug. 12, 2021 /PRNewswire/ -- According to the American Hair Loss Association (AHLA), an estimated 50 million men experience some level of hair loss and approximately 35 million women are also affected by thinning hair.
  • To help those who are suffering with this condition, National Hair Loss Awareness Month (NHLAM) delivers attention to detection, prevention, and treatment of these unfortunate yet oftentimes reversible statistics.
  • World-Renowned Hair Restoration Surgeon Dr. Alan J Bauman Announces New Technologies to Detect Prevent Treat Hair Loss
    The medical community also continues to see a correlation between COVID-19 and hair loss.
  • Trichotest Genetic Hair Loss Testing performs genetic testing based on state-of-the-art DNA microarray technology to identify the exact hair loss treatments that will perform best for the patient based on DNA analysis.